Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The MHC class I and class II antigen presentation machinery (APM) is a highly coordinated, multi-step cellular system responsible for processing intracellular and extracellular proteins into peptide fragments and displaying them on major histocompatibility complex (MHC) molecules at the cell surface. This machinery is fundamental to adaptive immunity, enabling CD8+ cytotoxic T cells and CD4+ helper T cells to survey the proteome for signs of infection, foreign antigens, or malignant transformation. Key components of this machinery include the immunoproteasome (for peptide generation), the Transporter associated with Antigen Processing (TAP) complex (for peptide translocation into the endoplasmic reticulum), the peptide-loading complex (including tapasin, calreticulin, and ERp57), and the MHC class I and II molecules themselves. In oncology, many tumors downregulate or mutate components of the APM (such as B2M or TAP1) to evade immune detection, leading to resistance against immune checkpoint inhibitors. Consequently, therapeutic strategies targeting the APM aim to restore or enhance its function using epigenetic modulators (like HDAC or DNMT inhibitors), EZH2 inhibitors, or cytokines (such as interferons) to increase tumor immunogenicity and overcome immune escape. Conversely, proteasome inhibitors like bortezomib directly disrupt this machinery to induce apoptosis in malignant cells.
Upregulation of MHC class I and II expression via epigenetic modulation, inhibition of proteasomal degradation of antigen precursors, and induction of antigen presentation machinery components via interferon signaling
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MHC class I and class II antigen presentation machinery (APM).